Ipraxa

Ipratropium bromide, the active ingredient in Ipraxa, is an anticholinergic (muscarinic antagonist) presented as an inhalation solution for inhalation use. It is used to treat chronic obstructive pulmonary disease and asthma by relaxing airway smooth muscle and reducing mucus secretion.

GNH USA supplies Ipraxa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipraxa is an inhaled anticholinergic bronchodilator indicated for diseases of the lower respiratory tract.

- Chronic obstructive pulmonary disease (COPD): improves airflow, reduces exacerbations and relieves dyspnea. - Asthma: provides bronchodilation as an adjunct to other controller therapies. - Bronchospasm: rapidly alleviates acute airway constriction. - Exercise‑induced bronchoconstriction: diminishes airway resistance during physical activity.

Common Side Effects: - Dry mouth: sensation of oral dryness. - Cough: mild irritation of the throat. - Throat irritation: discomfort during inhalation. - Headache: transient mild headache.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Angioedema: swelling of face, lips or tongue. - Severe allergic reaction: rash, itching, or anaphylaxis.

Before prescribing Ipraxa, consider the following precautions.

- Assess renal function: adjust use in severe impairment. - Monitor anticholinergic effects: watch for dry mouth, urinary retention, or blurred vision. - Avoid in patients with known hypersensitivity to ipratropium or formulation components. - Use with caution in patients with narrow‑angle glaucoma. - Store at room temperature: keep in the original container, protect from moisture and light.

Ipraxa may interact with other medications; monitor patients accordingly.

Major Interactions (Avoid): - Other anticholinergic drugs: additive anticholinergic effects may increase dryness or urinary retention. - MAO inhibitors: potential for hypertensive episodes.

Moderate Interactions (Monitor Closely): - Beta‑2 agonists: observe for enhanced bronchodilation and possible cardiovascular effects. - Theophylline: monitor serum levels for possible increased toxicity. - Inhaled corticosteroids: no significant interaction but assess overall respiratory response.